Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + Cyclophosphamide
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukaemia
Conditions
Acute Myeloid Leukaemia
Trial Timeline
Apr 1, 2016 → Dec 1, 2032
NCT ID
NCT02724163About Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + Cyclophosphamide
Gemtuzumab ozogamicin + Liposomal daunorubicin + Mitoxantrone + Fludarabine + Cytarabine + Busulfan + Cyclophosphamide is a phase 3 stage product being developed by Pfizer for Acute Myeloid Leukaemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02724163. Target conditions include Acute Myeloid Leukaemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02724163 | Phase 3 | Recruiting |
Competing Products
20 competing products in Acute Myeloid Leukaemia